Items tagged with Guidelines
Update of WHO guidelines on the management of latent TB infection (post)
01 July 2019 | Geneva: In July 2019, the World Health Organization (WHO) will convene a Guideline Development Group (GDG) to discuss what updates are needed to the current guidelines for programmatic management of latent tuberculosis infection (LTBI).
South-East Asia Regional Action Plan on the Programmatic Management of Latent Tuberculosis Infection launched at the 72nd Regional Committee (post)
05 September 2019 | New Delhi: Health Ministers and experts from Member States of WHO South-East Asia Region began a week-long meeting in New Delhi this week to deliberate on priority public health issues and build on the recent momentum for elimination of communicable diseases.
Update of WHO TB diagnostic guidelines: Call for public comment (post)
End-users (i.e. policy makers; health professionals, including doctors, nurses and educators working in governmental and non-governmental organizations; TB patients) interested in providing comments on the scope of this guideline update are invited to submit their feedback until 26 September 2019.
Information session on the TB Guideline Development Process: Please register (post)
The World Health Organization (WHO) is organizing an Information Session for civil society representatives to provide an update on the over WHO guidelines development process, with a focus on TB guideline development.
Report of the WHO Information Session for civil society representatives on the WHO guidelines development process with focus on TB guidelines (post)
9 October 2019, GENEVA - The World Health Organization (WHO) convened an Information Session for civil society representatives through webinar to provide an update on the WHO guidelines development process, with a focus on TB guidelines. The webinar was co-organized by WHO’s Global Tuberculosis Programme and Department on Quality, Norms and Standards of the Science Division, with participation from the Office of Compliance, Risk Management and Ethics. The Session was held on 9 October 2019, as part of an ongoing dialogue between WHO and civil society representatives. Over 250 representatives from civil society, partners and other stakeholders registered for the webinar. The information session was opened by Tereza Kasaeva, Director of the WHO Global TB Programme, who reiterated WHO’s close collaboration with civil society over the past years under the leadership of the WHO Director General Dr Tedros Adhanom Ghebreyesus.
WHO updates policy for the use of lateral flow urine lipoarabinomannan assay (LF-LAM) for diagnosing active TB in people living with HIV (post)
30 October 2019 | Geneva - The World Health Organization (WHO) has updated its guidance for the use of lateral flow urine lipoarabinomannan assay (LAM) in the diagnosis of tuberculosis (TB). Following new evidence, WHO now recommends a broader use of urinary LAM assays for diagnosis of TB in people living with HIV.
Meeting on update of the WHO drug-resistant TB treatment guidelines (post)
The Guideline Development Group convened a meeting on 12-14 November 2019 on update of the World Health Organization (WHO) drug-resistant TB treatment guidelines.
WHO releases new guidance on treating drug-resistant TB in children and adolescents (post)
WHO/Europe has released an expert opinion on managing drug-resistant tuberculosis (DR-TB) in children and adolescents, supported by a commentary in the Lancet.
WHO FAQs on key changes to the treatment of drug-resistant TB (post)
The World Health Organization (WHO) Global TB Program, in close collaboration with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the United States Agency for International Development (USAID) and the Global Drug Facility of the Stop TB Partnership have updated the Frequently Asked Questions (FAQs) document on WHO’s Rapid Communication: Key changes to the treatment of drug-resistant tuberculosis.
Short-course rifamycin-based regimens preferred for latent TB (post)
For treatment of latent tuberculosis infection (LTBI), short-course rifamycin-based regimens are preferred over longer-course isoniazid monotherapy, according to guidelines published in the Feb. 14 issue of the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Page 5 of 16 · Total posts: 0
←First 4 5 6 Last→